Mineralys Therapeutics (MLYS) is in focus after presenting new lorundrostat biomarker data at ENDO 2026 and announcing a US$150 million equity offering along with a US$500 million committed debt facility.

At a latest share price of US$24.63, Mineralys Therapeutics has seen its 30 day share price return fall 17.49%, even as the 1 year total shareholder return is 82.72% and 3 year total shareholder return is 54.42%. This suggests recent fundraising and clinical updates have shifted sentiment, while longer term momentum remains intact.

If you are interested in how other healthcare companies applying AI are performing, this is a good moment to scan the market using our screener for 40 healthcare AI stocks

With Mineralys Therapeutics now funded through a US$150 million equity raise and a US$500 million debt facility, yet trading well below some intrinsic value indicators, investors have to ask: is this a reset entry point, or has the market already baked in future growth?

Most Popular Narrative: 52% Undervalued

At a last close of $24.63 versus a narrative fair value of $50.88, Mineralys Therapeutics is framed as materially undervalued, with that gap driven by expectations around lorundrostat and its potential cardiorenal footprint.

Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile, which could materially affect future revenue and earnings visibility.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that valuation gap? The narrative leans on strong revenue build, a step change in margins and a premium earnings multiple tied to lorundrostat. The exact mix of those assumptions is where the story gets interesting.

Result: Fair Value of $50.88 (UNDERVALUED)

However, the Mineralys Therapeutics narrative still hinges on lorundrostat clearing regulatory hurdles and competing effectively, while ongoing losses and future funding needs could quickly change sentiment.

Next Steps

If this Mineralys Therapeutics story seems finely balanced between risk and reward, do not wait. Review the full picture and weigh up the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Mineralys Therapeutics?

Do not stop with Mineralys Therapeutics alone. Broaden your watchlist with a curated set of stock ideas surfaced by the Simply Wall St Screener for different goals and risk levels.

• Target potential mispricings by scanning a set of companies that currently screen as 45 high quality undervalued stocks before others catch on.
• Strengthen your income stream by reviewing a focused list of stocks screened as 8 dividend fortresses that may suit yield driven portfolios.
• Reduce portfolio stress by lining up a pool of companies highlighted as 66 resilient stocks with low risk scores so you can see which ones fit your comfort level.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.